Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$20.6B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help assess how well Roivant is managing its expenses relative to revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies to improve patient outcomes. With a market cap of $22 billion, it operates in the health care sector, which is increasingly important as the demand for new treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, increasing by nearly 15% the following day.

Management Promises & Guidance

Continue focusing on innovative therapies.
Expand partnerships to enhance research capabilities.
Maintain cost management to improve profitability.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Roivant has shown a tendency to beat EPS estimates in recent quarters. Investors will be keen to see if this trend continues.

Bull Case

If Roivant can deliver strong revenue growth and maintain its positive EPS surprises, it could signal robust operational performance and investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact stock performance.

How much is Roivant investing in R&D this quarter?

R&D spending is vital for future growth, and insights into this could indicate the company's commitment to innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's potential for revenue growth based on its recent partnerships and product pipeline developments.

Supporting Evidence

Roivant has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing in a larger move than the stock has historically experienced, suggesting heightened expectations.

Insider selling may indicate a lack of confidence in the near-term outlook, contrasting with the bullish sentiment.

Key Risk

If R&D spending significantly increases without corresponding revenue growth, it could undermine investor confidence.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Roivant's ability to maintain its growth trajectory against potential operational challenges.

Bull Confirmed If

Achieving an EPS of at least $0.30 would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.20 would likely confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a nearly 10% move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$14.4M

489,774 sh

2 insiders

Net

$14.4M

Net selling

Most Active Insiders· 2 open-market trades

CEOGline Matthew
$8.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 9.09%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 0.73%, as investors reassess the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the company's revenue growth and any new partnerships.
2Updates on the R&D pipeline and upcoming product launches.
3Management's outlook on market conditions and competitive landscape.
4Any changes to cost management strategies and their expected impact on profitability.
5Insights into insider selling and its implications for future performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help assess how well Roivant is managing its expenses relative to revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, increasing by nearly 15% the following day.

Management Promises & Guidance

Continue focusing on innovative therapies.
Expand partnerships to enhance research capabilities.
Maintain cost management to improve profitability.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Roivant has shown a tendency to beat EPS estimates in recent quarters. Investors will be keen to see if this trend continues.

Bull Case

If Roivant can deliver strong revenue growth and maintain its positive EPS surprises, it could signal robust operational performance and investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact stock performance.

How much is Roivant investing in R&D this quarter?

R&D spending is vital for future growth, and insights into this could indicate the company's commitment to innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's potential for revenue growth based on its recent partnerships and product pipeline developments.

Supporting Evidence

Roivant has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing in a larger move than the stock has historically experienced, suggesting heightened expectations.

Insider selling may indicate a lack of confidence in the near-term outlook, contrasting with the bullish sentiment.

Key Risk

If R&D spending significantly increases without corresponding revenue growth, it could undermine investor confidence.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Roivant's ability to maintain its growth trajectory against potential operational challenges.

Bull Confirmed If

Achieving an EPS of at least $0.30 would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.20 would likely confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a nearly 10% move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$14.4M

489,774 sh

2 insiders

Net

$14.4M

Net selling

Most Active Insiders· 2 open-market trades

CEOGline Matthew
$8.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 9.09%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 0.73%, as investors reassess the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the company's revenue growth and any new partnerships.
2Updates on the R&D pipeline and upcoming product launches.
3Management's outlook on market conditions and competitive landscape.
4Any changes to cost management strategies and their expected impact on profitability.
5Insights into insider selling and its implications for future performance.